Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
NEW YORK - Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to back out of agreements to jointly develop and market Aimovig for the prevention of migraines, and keep the profits for itself.
In a complaint filed in Manhattan federal court, Novartis said it has spent several hundred million dollars on Aimovig since August 2015, when it began collaborating with Amgen, which previously controlled all rights to the treatment. Novartis called Aimovig a “runaway success,” with about 210,000 patients using the drug in the United States and another 20,000 patients elsewhere.The lawsuit seeks to enforce the companies’ collaboration agreements, and declare Amgen’s purported termination void.Roughly 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. groupBiogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and...
Lire la suite »
Novartis pays $310 million upfront for inflammation specialist IFMNovartis on Monday said it had agreed to pay $310 million (£238 million) upfront...
Lire la suite »
Swiss drugmaker Novartis must face doctor kickback suit, U.S. judge rulesNovartis AG must face a U.S. government lawsuit accusing it of paying millions o...
Lire la suite »
'Fear' and health care: Gallup survey finds Americans skipped treatment, borrowed $88B to pay for costsA Gallup survey funded by West Health finds that Americans borrowed $88 billion to pay for health care last year
Lire la suite »
Amazon has quietly removed promotional spots that gave special treatment to its own productsAmazon has quietly removed some of its most aggressive promotions for private label products, following increased regulatory scrutiny of tech giants in recent months.
Lire la suite »
U.S. lawmakers urge sanctions over China's treatment of Muslim minorityA bipartisan group of U.S. lawmakers on Wednesday faulted the Trump administrati...
Lire la suite »